The CSL (ASX:CSL) share price has struggled to gain traction in 2022. Does that make it cheap?

Are CSL shares cheap with it being down over 10% this year?

| More on:
A compass with the word opportunities is shown in black and blue representing a broker upgrade on the EML share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price hasn’t been a strong performer in 2022
  • CSL shares are down 13% since the start of the year, does this mean it’s now cheap?
  • Some investors think that CSL is an opportunity

The CSL Limited (ASX: CSL) share price has struggled since the start of 2022. It's down over 13%. Does that mean that the ASX healthcare share is cheap?

It's now lower than it was at the bottom of the COVID-19 crash.

What's going on with the CSL share price?

My colleague Tony Yoo has quoted the fund manager Jun Bei Liu from investment manager Tribeca.

She said pointed out that healthcare names have underperformed, not because of the war but because they were expensive companies relative to other sectors.

There is also the prospect of much faster interest rate hikes to combat the high level of inflation that the world is seeing.

Billionaire Ray Dalio from investment group Bridgewater Associates once said about interest rates:

It all comes down to interest rates. As an investor, all you're doing is putting up a lump sum payment for a future cash flow.

The CSL share price initially rose after investors got a look at the result, but it has since dropped back.

To be able to call something "cheap", knowing how much profit a business is generating can be useful.

FY22 half-year result

CSL reported a net profit after tax (NPAT) of $1.67 billion for the first six months of FY22, which was down 5% in constant currency terms. However, revenue was up 4% in constant currency terms.

Management said that was strong growth in a number of areas for the business, whilst HPV royalties rebounded strongly (up 134%). Seqirus, the influenza vaccine business, was one of the segments that saw a strong performance with revenue up 17% in constant currency terms.

Ig and albumin sales were limited by constrained plasma collections in FY21.

In FY22, the net profit is expected to be in the range of between $2.15 billion to $2.25 billion at constant currency.

The interim dividend was increased by 8% in Australian dollar terms to A$1.46 per share.

Acquisition

The company also recently announced that it was acquiring Vifor Pharma, a global specialty pharmaceutical company with leadership in renal disease and iron deficiency.

Management said this will represent a meaningful acceleration of its 2030 strategy by further enhancing its focus on therapeutic leadership areas, innovation and sustainable growth.

Is the CSL share price a cheap buy?

When talking about CSL, Resmed CDI (ASX: RMD) and Cochlear Limited (ASX: COH), the fund manager Liu said:

All of them have reported pretty good numbers… And since then the share prices have come off again

All of that together makes these companies absolute standouts. When there's a rebound it is these companies that will be the first ones to move [upwards]. They have pricing power. They can apply faster price increases so that their earnings growth is not going to be impacted. These companies will continue to grow.

Plenty of brokers also think that CSL is a buy, such as Citi, with a price target of $335. Morgans is another broker with a positive outlook – it rates CSL as a buy with a price target of $327.60.

On Citi's numbers, the CSL share price is valued at 30x FY23's estimated earnings.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. and Cochlear Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Down 20%, is the NIB share price undervalued?

Here's what Goldman Sachs is saying about this blue chip stock.

Read more »

four excited doctors with their hands in the air
Healthcare Shares

Sigma Healthcare shares rocket 39% on Chemist Warehouse merger approval

The ACCC doesn't believe the company's merger with Chemist Warehouse will lessen competition.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

ASX 200 healthcare stock rockets on $75 million news

This marks another positive step for the company.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »